Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.17 Consensus PT from Analysts
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) has received a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to […]
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) has received a consensus recommendation of “Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to […]
